Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a magnetic headset boost brain power after injury or illness?

NCT ID NCT07600320

Symptom relief Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests whether a low-level magnetic therapy device, used at home, is safe and practical for people with cognitive issues from brain injury, Long COVID, or Alzheimer's. About 30 adults will use the device regularly and complete computer-based thinking tests. The goal is to gather initial data to plan larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

IncInclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Any sex/gender * 16 years of age or older * English Speaking * Experiencing symptoms of at least self-reported mild cognitive impairment associated with a confirmed diagnosis of a condition such as Long COVID, Traumatic Brain Injury, other Acquired Brain Injuries, and other neurodegenerative diagnoses including but not limited to Alzheimer's disease * Individuals of childbearing age agreeing to use a highly effective form of birth control for the duration of their participation * Willing and able to sign informed consent or have a parent or LAR able to sign informed consent form * Willing and able to attend all study visits virtually or in person Exclusion Criteria: Individual who meets any of the following criteria will be excluded from participation in this study: * Enrollment in another interventional clinical trial in the last 90 days or during the study period * Change in anti-depressant or other psychoactive medication or dose in the last 90 days * Cranially implanted devices or metal * Pacemaker * History of seizure disorder * Pregnant or plan to become pregnant during the study as indicated by proof of a positive pregnancy test * Inability to achieve appropriate positioning of the study device on the head * Any medical, psychiatric, or neurological condition, or concurrent treatment, that in the opinion of the Principal Investigator would interfere with study participation, interpretation of results, or pose additional risk to the participant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acquired brain injury are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Brain Injuries, Traumatic brain injury cognitive disorder Cognitive Dysfunction long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome traumatic brain injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acquired brain injury Cognitive dysfunction Traumatic brain injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.